Diagnostic Value of Resistive Index of the Renal Interlobar Artery in Type 1 Cardiorenal Syndrome
-
摘要:
目的 探讨彩色多普勒超声测量肾脏叶间动脉阻力指数(resistance index, RI)对Ⅰ型心肾综合征(cardiorenal syndrome, CRS)的诊断价值。 方法 选取2017年6月1日至2018年3月1日收住民航总医院急诊综合病房并诊断为Ⅰ型CRS的20例患者作为试验组(CRS组), 选取同期诊断为单纯急性心力衰竭的患者20例作为对照组, 分析两组患者的临床特征、实验室检查及用药情况, 并根据受试者工作特征(receiver operating characteristic, ROC)曲线评价肾动脉RI对Ⅰ型CRS的诊断价值。 结果 两组患者年龄、左心室射血分数、心功能分级、心率及脉压差差异无统计学意义(P均>0.05), CRS组患者的氨基末端脑钠尿肽、肌酐水平、呋塞米剂量以及肾动脉RI均高于对照组, 而肾小球滤过率低于对照组, 差异具有统计学意义(P均 < 0.05)。ROC曲线下面积为0.78, 取最佳截点值0.70时预测Ⅰ型CRS的敏感度为80%, 特异度为80%。 结论 作为一种新的手段, 肾动脉RI可与传统方法相互补充, 对诊断Ⅰ型心肾综合征患者具有潜在应用价值。 Abstract:Objective This study aimed to discuss the diagnostic value of the resistance index (RI) of the renal interlobar artery measured by color Doppler ultrasound in patients with type 1 cardiorenal syndrome(CRS). Methods Twenty patients with type 1 CRS diagnosed in emergency wards were defined as group CRS; 20 patients diagnosed as heart failure in the same period were defined as the control group. Clinical features, laboratory examination and medication of the two groups were analyzed. The RI of the two groups of patients was measured. The diagnostic value of RI in type 1 CRS was evaluated according to the receiver operat-ing characteristic(ROC) curve. Results There was no significant difference in age, left ventricular ejection fraction (LVEF), heart rate, pulse arterial pressure, and cardiac function classification between the two groups(all P>0.05). The level of N-terminal pro-brain natriuretic peptide, creatitine, and RI of CRS group were higher than those in the control group; the glomerular filtration rate in group CRS was lower than that in the control group, and the difference was statistically significant (all P < 0.05). The area under the ROC curve was 0.78 and the best cut-off point was 0.70. The sensitivity was 80% and the specificity was 80%. Conclusions As a new means, the RI of the renal interlobar artery can complement traditional methods and has a potential value in the diagnosis of type 1 CRS. 利益冲突 无 -
表 1 Ⅰ型CRS患者与单纯急性心力衰竭对照患者一般临床资料比较
指标 CRS组(n=20) 对照组(n=20) t值/χ2值 P值 性别(男/女,n) 13/7 15/5 0.476 0.490 年龄[x±s,岁] 68.9±17.6 65.5±10.1 0.892 0.941 心率(x±s, 次/min) 79.3±18.5 84.7±16.1 -0.787 0.886 脉压差(x±s, mm Hg) 44.6±15.2 52.3±11.6 6.316 0.347 体质量指数(x±s, kg/m2) 27.7±6.9 25.4±9.8 2.239 0.260 心力衰竭诱因[n(%)] 3.154 0.926 高血压 9(45) 8(40) 冠心病/心肌缺血 5(25) 5(25) 心肌瓣膜病 3(15) 5(25) 心律失常 2(10) 1(5) 其他 1(5) 1(5) 心功能分级[n(%)] 1.543 0.462 Ⅱ级 3(15) 6(30%) Ⅲ级 12(60) 11(55%) Ⅳ级 5(25) 3(15%) 既往病史[n(%)] 1.067 0.900 高血压 10(50) 8(40) 冠心病/心肌缺血 5(25) 4(20) 糖尿病 2(10) 3(15) 高脂血症 2(10) 3(15) 其他 1(5) 2(10) 预后[n(%)] 3.137 0.077 好转 15(75) 19(95) 28 d死亡 5(25) 1(5) 胆固醇[n(%)] 0.417 0.519 升高 13(65) 11(55) 正常 7(35) 9(45) 伴随治疗用药[n(%)] 0.925 0.819 ACEI/ARB 8(40) 7(35) β受体阻滞剂 5(25) 7(35) 洋地黄类药物 13(65) 10(50) 血管活性药物 14(70) 16(85) CRS:心肾综合征;ACEI:血管紧张素转换酶抑制剂;ARB:血管紧张素受体阻滞剂 表 2 Ⅰ型CRS患者与单纯急性心力衰竭对照患者相关实验室检查及用药比较
指标 CRS组(n=20) 对照组(n=20) t值/Z值 P值 NT-proBNP[M(QR), pg/ml] 36 529(4344, 12 396) 14 986(1479, 7893) 2.184 0.031 肌酐(x±s, μmol/L) 159.8±44.3 84.9±37.6 5.552 <0.010 左心室射血分数(x±s, %) 41.6±12.3 50.1±18.6 -0.559 0.587 心功能分级(x±s) 2.6±1.2 2.3±1.0 0.718 0.483 肾小球滤过率[x±s, ml/(min·1.73 m2)] 77.8±18.5 103.9±17.4 3.211 0.024 肾动脉RI(x±s) 0.73±0.06 0.67±0.05 2.115 0.043 呋塞米剂量(x±s, mg/d) 127.7±54.0 97.6±61.2 4.335 0.012 CRS:同表 1; RI:阻力指数;NT-proBNP:氨基末端脑钠尿肽 表 3 肾动脉高阻组患者与低阻组患者临床指标比较
指标 RI>0.70(n=24) RI≤0.70(n=16) t值/Z值 P值 年龄(x±s,岁) 75.3±12.4 61.9±16.9 2.369 0.028 NT-proBNP[M(QR), pg/ml] 18 033(5994, 34 244) 7816(3574, 9430) 5.927 0.047 肌酐(x±s, μmol/L) 133.6±47.2 80.1±30.0 0.956 0.015 心功能分级(x±s) 2.9±1.1 2.5±0.8 -0.841 0.039 肾小球滤过率[x±s, ml/(min·1.73 m2)] 73.7±19.1 99.5±17.2 3.329 <0.010 脉压差(x±s,mm Hg) 57.4±14.3 45.9±16.6 2.154 0.040 呋塞米剂量(x±s, mg/d) 118.6±36.9 101.4±54.7 -0.718 0.790 体质量指数(x±s, kg/m2) 28.2±7.1 26.4±10.3 0.597 0.581 心率(x±s, 次/min) 79.6±13.9 71.2±18.0 -0.565 0.634 RI、NT-proBNP:同表 2 -
[1] Ronco C, Bellomo R, McCullough PA, et al.Cardiorenal syndromes:report from the consensus conference of the acute dialysis quality initiative[J].Eur Heart J, 2010, 31:703-711. doi: 10.1093/eurheartj/ehp507 [2] 杨叶猗, 肖力, 刘伏, 等.心肾综合征临床诊断与监测的生物标记物[J].中华临床医师杂志(电子版), 2013, 7:2300-2303. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhlcyszz201306003 [3] Virzi GM, Breglia A, Brocca A, et al.Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1[J].Cardiorenal Med, 2018, 11, 8:321-331. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=d9404d1bc4e6053aeb7eccd47f55aa39 [4] 贺秀红, 车岩, 杨敬英, 等.彩色多普勒超声对心肾综合征肾内动脉血流的评价[J].兰州大学学报(医学版), 2008, 34:68-70. http://d.wanfangdata.com.cn/Periodical/lanzyxyxb200802020 [5] Elodie G.The Origins of the Prospective Cohort Study:American Cardiovascular Epidemiology and the Framingham Heart Study[J].Rev Hist Sci, 2011, 2:297-318. http://www.cairn-int.info/article-E_RHS_642_0297--the-origins-of-the-prospective-cohort.htm [6] Kidney Disease Improving Global Outcomes(KDIGO) Acute Kidney Injury Work Group.KDIGO Clinical Practice Guideline for Acute Kidney Injury[J].Kidney Int, 2012, 2:1-38. doi: 10.1038/kisup.2012.1 [7] Cirillo M.Rationale, pros and cons of GFR estimation:the Cockcroft-Gault and MDRD equations[J].G Ital Nefrol, 2009, 26:310-317. http://www.ncbi.nlm.nih.gov/pubmed/19554528 [8] BongartzL G, Cramer MJ, Doevendans PA, et al.The severe cardiorenal syndrome:'Guyton revisited'[J].Eur Heart J, 2005, 26:11-17 doi: 10.1093/eurheartj/ehi020 [9] Di Lullo L, House A, Gorini A, et al.Chronic kidney disease and cardiovascular complications[J]. Heart Fail Rev, 2015, 20:259-272. doi: 10.1007/s10741-014-9460-9 [10] Ronco C, Lullo LD. Cardiorenal Syndrome in Western Countries:Epidemiology, Diagnosis and Management Approaches[J].Kidney Dis, 2016, 2:151-163. doi: 10.1159/000448749 [11] Atici A, Emet S, Cakmak R, et al. Type Ⅰ cardiorenal syndrome in patients with acutely decompensated heart failure:the importance of new renal biomarkers[J].Eur Rev Med Pharmacol, 2018, 22:3534-3543. http://europepmc.org/abstract/MED/29917208 [12] Wei L, Ye X, Pei X, et al.Diagnostic accuracy of serum cystatin C in chronic kidney disease:a meta-analysis[J].Clin Nephrol, 2015, 84:86-94 http://europepmc.org/abstract/MED/26200185 [13] Verbrugge FH, Damman K, Tang WHW. Diuretics in cardiorenal syndrome:what's new?[J].Intensive Care Med, 2018, 44:359-362. doi: 10.1007/s00134-017-4834-9 [14] 罗竞超, 邱晓华, 邱海波.肾动脉阻力指数在重症患者急性肾损伤评估中的应用[J].中华内科杂志, 2014, 53:496-498. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201406023 [15] 许书添, 李世军.肾静脉高压与急性肾损伤[J].肾脏病与透析肾移植杂志, 2015, 6:557-561. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=szbytxsyzzz201506014 [16] 陈秀凯, 杨荣利.感染性急性肾损伤:几个热点问题的冷思考[J].协和医学杂志, 2017, 8:336-341. http://www.cnki.com.cn/Article/CJFDTotal-XHYX201706005.htm [17] 李偲, 杜小刚.心肾综合征研究进展[J].中华临床医师杂志(电子版), 2015, 9:833-837. [18] Lacoviello M, Monitillo F, Leone M, et al.The Renal Arterial Resistance Index Predicts Worsening Renal Function in chronic Heart Failure Patients[J].Cardiorenal Med, 2016, 6:116-128. doi: 10.1159/000442300 [19] 张晓东, 李建初.肾动脉阻力指数新认识[J].中国继续医学教育, 2017, 9:86-88. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgjxyxjy201722043 -